Navigation Links
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
Date:8/23/2007

FDA Approved Product Will Accelerate Growth of Pain Franchise

FRAZER, Pa., Aug. 23 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today it has signed an agreement to acquire the North American rights to AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) from ECR Pharmaceuticals, a privately held company. Two dosage strengths of AMRIX (15 mg and 30 mg) were approved in February 2007 by the U.S. Food and Drug Administration (FDA) for short-term use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The product is not yet available commercially in the United States; however, Cephalon expects to launch the product early in the fourth quarter.

Under the agreement, which is expected to close on or about August 28, 2007, Cephalon will acquire the rights to AMRIX for $100 million cash. The company also could make future cash payments to ECR upon the achievement of certain cumulative net sales milestones. The company anticipates that the transaction will be modestly dilutive in the fourth quarter due to product launch costs; despite this, the company is reaffirming its existing 2007 sales and adjusted income per common share guidance. The transaction is expected to be accretive in 2008 and thereafter.

"AMRIX is an excellent strategic fit with our current sales organization, providing us with a second product that is complementary to many pain relievers used today," said Robert Roche, Executive Vice President, Worldwide Pharmaceutical Operations. "Cyclobenzaprine HCl is the most widely prescribed muscle relaxant in the United States, representing 37 percent of the 45 million prescriptions for muscle relaxants written in 2006, according to IMS. AMRIX has convenient once-daily dosing and a side effect profile that includes very low rates of sedation which will provide physicians and patients an attractive alternative to current therapies.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ire/ -- MedImmune today announced that,it has ini...hronic asthma to,determine the safety of subcutan...Ab) that targets the interleukin-5 receptor (IL-5R...L-5R pathway may lead to a targeted approach for,...d study of this antibody. , "Asthma can be ...
(Date:12/4/2008)...08 and Full Year 2009 Earnings Guidance , , ...all/ -- DuPont, (NYSE: DD ) today announced fur...and strengthen the company,s competitiveness in 20...low, and provided earnings guidance for the fourth... steep global decline in construction and motor ve...
(Date:12/4/2008)...-- Parion Sciences, Inc. today announced,that its...nitiated a Phase I,clinical trial of GS9411 in he...ability of the investigational compound. GS9411 i...reatment of pulmonary disease. Previously known a...ENaC) blocker discovered by,Parion, a privately h...
(Date:12/4/2008)...rstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ,...used on endocrine therapy and oncology, today anno...h.D., will take part in a panel discussion titled,...nts" at the upcoming RBC Capital Markets 2008 Heal...at 4:30 pm (eastern time) at the Westin Times Squa...
Breaking Biology Technology:MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow 2DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow 3DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow 4DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow 5DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow 6Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 2Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 3
...nologies Incorporated has closed its acquisition ...for $6 million in cash. Both companies make medica...ols has renewed through 2010 its deal to buy mana...tworks , a global telecom headquartered near Toron...rcing nearly all the management of their network a...
...ly a banner year for venture capital investments i... MoneyTree report, which is based on data from the...at does this mean for the life science industry? ,...re particularly, what does it mean for the Midwest...l down to this level and find out (I can hear the ...
... Zhang received another boost to his stem-cell res...el J. Fox Foundation . Zhang, an assistant profess...isconsin-Madisons stem-cell research program, will...ns Cell Line II program and will be paid in instal...The work done by Zhangs team centers on finding th...
...t is showing a pulse again, Midwest technology CEO...ering: Which employee is going to surprise them wi... the clock ticking on a two-week notice period? , ...e, its also disconcerting to a manager whos on the...ed integration project or just keep the firms engi...
Other Biology Technology:Life-science sector grabbed VC investment in 2004 2Life-science sector grabbed VC investment in 2004 3Stem-cell research gets grant from M.J. Fox Foundation 2Keep your tech employees happy 2Keep your tech employees happy 3Keep your tech employees happy 4
(Date:12/4/2008)...rium overcomes a tomato plant,s defences and cause...uder detection systems, is,revealed in new resear..., The new study focuses on a pathogen which caus... bacterial invasion causes black lesions on leaves...and costly damage to,tomato crops, and researcher...
(Date:12/4/2008)...half of a person,s body mass consisting of skeleta...hich include those found in the limbs can result ...to University of Illinois kinesiology and communit...s demonstrated that the antioxidant properties of ...n of certain pro-inflammatory cytokines, in vitro,...
(Date:12/4/2008)...earthquakes and destructive tsunamis over the past...nother large earthquake, warns an international gr...shed in the Dec. 4 issue of the journal Nature . ...agnitude 9.2 in December 2004, produced the most w.... The cause of that calamity was the rupture of a...
(Date:12/4/2008)...AA new and improved tool to monitor deforestation ...n a huge boost. The Gordon and Betty Moore Foundat...ent of Global Ecology with a $1.6-million grant to... Analysis System Lite), a new, user-friendly metho...on-governmental organizations (NGOs) to map tropic...
Breaking Biology News(10 mins):Red alert! How disease disables tomato plant's 'intruder alarm' 2Vitamin E shows possible promise in easing chronic inflammation 2Vitamin E shows possible promise in easing chronic inflammation 3September 2007 Sumatran earthquakes research findings 2September 2007 Sumatran earthquakes research findings 3Tropical forest carbon monitoring gets big boost 2Marital Status Doesnt Affect Lung Cancer Survival 1121 1Marital Status Doesnt Affect Lung Cancer Survival 1121 2Marital Status Doesnt Affect Lung Cancer Survival 1121 3Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2405 1Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2405 2Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2405 3Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2405 4Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4 2008 8919 1Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4 2008 8919 2Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4 2008 8919 3Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4 2008 8919 4Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4 2008 8919 5Holiday Travel Bad Eating Habits a Recipe for Stomach Trouble 8916 1Holiday Travel Bad Eating Habits a Recipe for Stomach Trouble 8916 2
... group of Montreal researchers has discovered that...sion of new information into long-term memory, may...rm to long-term memory. Their paper Translational ...ory by the eIF2a kinase GCN2, which was published ...ovides the first genetic evidence that protein syn...
...olecular motors are nanoscale engines which move a..., drive the heavy traffic of molecular cargo withi...be isolated from the cells and used to construct b...the flux of the cargo transport, it would be neces...ute to this transport but, at the same time, avoid...
...y deciphering the ingenious mechanism used by a pa...mistry, scientists have come a step closer to desi...bacterial infections in their tracks. Their resear...rnal Cell. , Scientists have known for many years ...ferase) plays a role in regulating gene expression...
...ew research on a bacterium that can survive encoun...hened scientists, belief that these plentiful whit...er our immune system will permit or prevent bacter...s released today online in The Journal of Immunolo...atories (RML), part of the National Institute of A...
Other Biology News:Montreal researchers probe the genetic basis of memory 2Motor transport in bio-nano systems 2Motor transport in bio-nano systems 3Motor transport in bio-nano systems 4Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3
I-Ab MHC Class II
...orporates the critical design features demanded by...marker research. The Series 4000 delivers improved...rting biomarker discoveries to biomarker assays al...d to fit into the research plans of any life scien...
BssH II Bacillus stearothermophilus from Sigma-Aldrich
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,369-4) or contact custom
Biology Products: